Further, treatment with engineered iNK cells markedly improved survival over non-engineered iNK and control mice, demonstrating the potency of the CD73/CD155 co-targeting engineered NK cell therapy in treating GBM (Fig. 5F). This evidence concerns the gene PVR and glioblastoma.